Pretreatment with low-dose IL-1 has protective effects in animal models of inflammation or tissue injury, but the mechanisms of these protective effects are not established. To determine if prostaglandins are involved, we administered human recombinant IL-1ft and measured rectal PGE2 production in rabbits with formalin-immune complex colitis. (0.3 gg/kg) administered 24 h before induction of colitis increased PGE2 (231±36 to 1,299±572 pg/ml, P < 0.01) and reduced subsequent inflammatory cell infiltration index (from 2.8±03 to 1.4±0.3, P < 0.02) and edema (from 2.5±03 to 13±03, P < 0.01) compared with vehicle-matched animals. Administration of ibuprofen (10 mg/kg i.v.) together with IL-ift prevented the stimulation of PGE2 and the reduction in inflammation. Colonic PGE2 production correlated inversely with subsequent severity of inflammation (P < 0.02, r = -039) and edema (P < 0.04, r = -0.35). IL-i-administration 30 min before induction of colitis did not affect the severity of inflammation. Similarly, pretreatment with a noninflammatory synthetic peptide (fragment 163-171) of human IL-iS, either 30 min or 24 h before colitis induction, did not reduce inflammation or increase prostaglandin synthesis. These data demonstrate that pretreatment with IL-lif 24 h before the induction of colitis reduces inflammation by a mechanism that requires prostaglandin synthesis. (J. Clin. Invest. 1990. 85:582-586.) interleukin 1 -prostaglandin E2 -colitis
and radiation (6, 7) , contact hypersensitivity (8) , -and arthritis (9) . The mechanisms of these protective effects of IL-I pretreatment are not established and may involve different actions of IL-I in the various models. A role for IL-1-stimulated prostaglandin production has been suggested in the cutaneous hypersensitivity model, because indomethacin abrogates the protective effects of IL-1, and exogenous prostaglandins produce protection similar to IL-1 (8) .
We have recently demonstrated that infusions ofIL-la and IL-I# into perfused rabbit colon and incubations of IL-l with colon tissue induce enhanced prostaglandin production (10) . There is increasing evidence that prostaglandins have protective effects in chemical, infectious, and immunological damage ofcolon mucosa (1 1-14) . Our studies have also shown that pretreatment of rabbits with the prostaglandin analogues, 16,16-dimethyl-PGE2 percutaneously or misoprostol by enema, markedly reduces the subsequent severity of colon inflammation in the formalin-immune complex model (15, 16) . Therefore, we hypothesized that pretreatment with low-dose IL-1# would enhance prostaglandin production and reduce inflammatory damage in the rabbit model of formalin-immune complex colitis (17) . This model provides a system to test the theory. Local prostaglandin production can be measured by validated rectal dialysis techniques, and inflammation may be quantitated by established histologic criteria (18 (19) . This preparation has a specific activity of 1010 U/mg based upon the DIOS (subclone of the DlO.G4 T cells) assay (20 Qantitation of inflammation. Animals were killed 48 h after induction of colitis, and the distal colon removed, coded, and processed for routine light microscopy. All samples were examined in a blind fashion by a single pathologist (Dr. C. C. Nast). Two representative longitudinal sections from each colon were examined as previously described (18) . A minimum of eight high-power fields of the mucosa and submucosa from each specimen were separately evaluated for acute inflammatory cells infiltrates (neutrophils and eosinophils). A semiquantitative score of leukocytes per high-power field (1/hpf)' was determined for each area examined using the following quantitations: 0 = 0 or 1 l/hpf; 0.5+ = 2-9 1/hpf; 1+ = 10-20 1/hpf; 1.5+ = 21-30 l/hpf; 2+ = 31-40 l/hpf; 2.5+ = 41-50 1/hpf; 3+ = 51-65 1/hpf; 3.5+ = 66-80 l/hpf; 4+ = 2 81 l/hpf. The inflammatory index was considered the sum of the averaged mucosal and submucosal scores. Edema was graded on a scale of 0-4+. PGE2 radioimmunoassay. PGE2 was measured in rectal dialysates by validated radioimmunoassay after lipid extraction and purification by Sephadex LH-20 chromatography (24) .
Statistical analysis. Results are expressed as mean±SEM. Statistical analysis was performed using a statistical software (BMDP Inc., Los Angeles, CA). Statistical comparisons were performed using the Wilcoxon rank sum test. Correlations were evaluated using the Pearson's r test. The differences were considered significant when the P value was < 0.05.
Results
Effect of IL-J# pretreatment on severity of inflammation.
Human recombinant IL-IjB (0.3 Ag/kg) administered 30 min before induction of colitis did not influence the subsequent severity of colonic inflammation compared with that of placebo-treated colitis animals (Table I ). In contrast, IL-I# administered 24 h before colitis induction markedly reduced inflammatory cell index and edema (Table I) . A separate group of eight animals, treated with IL-Il# 24 h before induction of colitis, additionally received the cyclooxygenase inhibitor ibuprofen (10 mg/kg diluted in sterile saline intravenously; Sigma Chemical Co., St. Louis, MO), 10 min before the IL-fl# infusion. The severity of colonic inflammation in this group was similar to the inflammation in the placebo-treated colitis animals and significantly greater than inflammation in the group that received only IL-1 24 h before colitis induction (Table I) . Representative histologic sections from each experimental group are shown in Fig. 1 .
Additional studies examined the effect of ibuprofen (10 mg/kg i.v.) administered 24 h before induction of colitis. Compared with eight matched placebo-treated colitis animals, ibuprofen had no detectable effect on inflammatory cell infiltration index (3.5±0.4 vs. 3.2±0.3) or edema (2.9±0.3 vs.
2.6±0.3).
Effect of 163-171 peptide pretreatment on severity of inflammation. The nonapeptide was administered in doses of 30 and 300 .g/kg. There were no significant effects of the nonapeptide, administered either 30 min or 24 h before induction 1 . Abbreviation used in this paper: 1/hpf, leukocytes per high-power field. ofcolitis, on inflammatory cell index or edema compared with simultaneous placebo controls (Table II) .
Effect of IL-I preparations on colonic PGE2 production.
Data of colonic PGE2 production measured by rectal dialysis in the 2-h period immediately before induction of colitis are shown in Fig. 2 . IL-lI given 30 min before induction of colitis did not alter PGE2 (315±124 pg/ml) compared with vehicletreated animals (231±36). In contrast, IL-lI# given 24 h before colitis significantly increased PGE2 (1,229+572, P < 0.01) compared with vehicle. Ibuprofen together with IL-I abolished the increase in PGE2 production associated with 24-h IL-I pretreatment (244±174). There appeared to be an inverse relationship between PGE2 production measured before induction of colitis and the subsequent severity ofinflammatory cell index (P < 0.02, r = -0.39) and edema (P < 0.04, r = -0.35), suggesting that endogenous prostaglandin stimulation may have protective activity. The nonapeptide fragment of IL-1,, administered in either dose at 30 min or 24 h before induction of colitis, did not alter PGE2 production compared with vehicle (Fig. 2) .
Discussion
These studies demonstrate that pretreatment with a relatively low dose ofhuman recombinant IL-I 24 h before initiation of colitis markedly diminishes the severity of inflammation measured 48 h after colitis induction in the rabbit model of formalin-immune complex colitis. Pretreatment 30 min before initiation of colitis does not have protective effects. Thus, the protective effect appears to be time dependent in relation to the immune stimuli. Similarly, IL-1 induction of enhanced prostaglandin production in the isolated perfused rabbit colon is also time dependent, requiring several hours of IL-1 infusion to obtain maximum effect (10). In the current study, increased in vivo production ofprostaglandins was documented -24 h, but not within 30 min, after IL-1 administration. These data are consistent with the concept that, in some animal models, IL-1 protection may require induction of a secondary mediator, possibly synthesis of prostaglandin-generating enzymes (27) . Generation of a secondary mediator, such as prostaglandins, has also been proposed as the mechanism by which sub- lethal doses of IL-1 protect against subsequent administration of lethal doses in the mouse (28) . Pretreatment with the cyclooxygenase inhibitor ibuprofen prevented the IL-1 stimulation of prostaglandin synthesis and abrogated the protective effect of IL-1. Our earlier studies demonstrated that pretreatment of animals with either parenteral 16,16-dimethyl-PGE2 or local misoprostol, a PGEI analogue, was also protective in the colitis model (15, 16 ). In the model of contact hypersensitivity, indomethacin pretreatment similarly prevented the protective effects of IL-1, and prostaglandin administration mimicked IL-1 protective effects (8) . Thus, the protective effects of IL-1 pretreatment may involve stimulation of increased prostaglandin synthesis in these models.
Colon prostaglandin production was increased 24 h after IL-1 injection, immediately before induction of colitis. This preinduction of PGE2 correlated inversely with the subsequent severity of colon inflammation, supporting the concept that PGE2 protects against development of inflammation. In contrast, PGE2 production measured 48 h after induction ofcolitis correlates positively with the severity of inflammation (18) . Administration of 16,16-dimethyl-PGE2 or misoprostol after induction of colitis is ineffective in reducing inflammation (unpublished observations). Thus, protection requires enhanced amounts of prostaglandins before the noxious or immune stimuli. The mechanism of prostaglandin protection is not established and may involve inhibition ofleukotriene production (29) , inhibition of cytokine production by increasing intracellular cyclic adenosine monophosphate (30) , or suppression of immune response including inhibition of mitogen responsiveness, clonal proliferation, and antigenic stimulation (31, 32).
The 163-171 peptide fragment of human IL-I(# has immunomodulatory actions similar to complete IL-1 , including T cell activation with enhanced antibody response (22) . Pretreatment with this nonapeptide is also radioprotective and restores immune reactivities after sublethal irradiation (23) .
The HQ salt (the preparation used in our studies) is equipotent to intact IL-I in each of these actions. In contrast, the 163-171 fragment lacks several ofthe acute-phase and inflammation-related effects of IL-l, including lack of pyrogenic effects, decreases in plasma iron and glucose, and increases in insulin, corticosteroids, and fibrinogen (21, 22) . In addition, the nonapeptide fragment fails to stimulate prostaglandins from dermal fibroblasts (21) . Thus, the nonapeptide was administered in our study to determine if it would display protective effects without stimulating prostaglandin synthesis. However our study demonstrates that the 163-171 fragment of human IL-1A3, in doses 100-and 1,000-fold greater than IL-1, does not have protective effects or stimulate prostaglandins in this model. Enhanced prostaglandin production may not be the protective mechanism in other animal models. Administration of IL-I several hours before the noxious stimuli is not necessary for protection in some models of injury, including oxygen-induced lung injury (33) and antigen-induced arthritis (9) . Furthermore, ibuprofen does not prevent IL-1 protection from gram-negative bacterial infection (5) .
Taken together, our data suggest that pretreatment with IL-I reduces the severity of inflammation in the formalin-immune complex colitis by enhancing production of colon prostaglandins. The protective effect is time dependent, possibly involving the induction of new prostaglandin-synthesizing enzymes. 
